XML 40 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaborative Agreement (Details)
 1 Months Ended 2 Months Ended 9 Months Ended 12 Months Ended
May 26, 2017
USD ($)
Installments
May 06, 2016
USD ($)
$ / shares
shares
Feb. 28, 2017
USD ($)
$ / shares
shares
Sep. 30, 2015
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Sep. 30, 2016
USD ($)
Dec. 29, 2015
USD ($)
Collaborative Agreement (Textual)                
Amount received from BriVision       $ 22,517 $ 953,000   $ 6,500,000  
Common stock newly issued, value       $ 51,958     $ 3,250,000  
Collaborative Agreement [Member]                
Collaborative Agreement (Textual)                
Description of payment settlement schedule        
 ● upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.
   
  upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
   
 ●at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.
   
 ●upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
   
 ●at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.
   
 ●upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.
  
 ● upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.
   
  upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
   
 ●at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.
   
 ●upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
   
 ●at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.
   
 ●upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.
  
Amount received from BriVision               $ 100,000,000
Upfront payments             $ 3,500,000  
Percentage of payments under collaborative agreement             3.50%  
Milestone payments to BioLite in cash   $ 2,600,000            
Common stock newly issued, value   $ 900,000            
Common stock newly issued, shares | shares   562,500            
Share price | $ / shares   $ 1.60            
Licensing rights         $ 10,000,000   $ 10,000,000  
Collaborative Arrangement One [Member]                
Collaborative Agreement (Textual)                
Description of payment settlement schedule         Pursuant to the Collaborative Agreement, 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of our common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares.      
Percentage of payments under collaborative agreement           6.50% 6.50%  
Milestone payments to BioLite in cash     $ 650,000          
Common stock newly issued, value     $ 5,850,000          
Common stock newly issued, shares | shares     2,925,000          
Share price | $ / shares     $ 2.0          
Accounts payable           $ 6,500,000 $ 6,500,000  
Co-Dev Agreement [Member]                
Collaborative Agreement (Textual)                
Cash receivable from Rgene $ 3,000,000              
Number of installments | Installments 3              
Proceeds from cash received $ 240,000              
Future net licensing income, percentage 50.00%